Summary
In a randomized, double blind, placebo-controlled study 36 patients aged 16–77 years who had been carriers of nontyphi Salmonella species for 10–21 weeks were given the combination pivampicillin/pivmecillinam or placebo for four weeks in order to eradicate the carrier state. 34/36 patients who fulfilled the criteria for inclusion in the study were evaluable for efficacy, 16 in the pivampicillin/pivmecillinam group and 18 in the placebo group. Seven patients in the pivampicillin/pivmecillinam group had to terminate the treatment after 10–25 days because of adverse reactions, mainly exanthema and nausea. After therapy 8/16 patients treated with pivampicillin/pivmecillinam and 4/18 patients treated with placebo had negative stool cultures for Salmonella species during a mean follow-up time of 13 and 20 weeks, respectively. No abnormalities could be found in those patients who did not respond to therapy except for earlier cholecystectomy in two patients, both in the pivampicillin/pivmecillinam group.
Zusammenfassung
In einer randomisierten, placebokontrollierten Doppelblindstudie erhielten 36 Patienten im Alter von 16 bis 77 Jahren, die Träger nicht typhöser Salmonellenspezies über einen Zeitraum von 10 bis 21 Wochen waren, vier Wochen lang entweder Pivampicillin/Pivmecillinam, um das Trägerstadium zu beenden oder Placebo. Die Wirksamkeit dieser Maßnahme konnte bei 34/36 der Patienten, die die Aufnahmekriterien in diese Studie erfüllten, ausgewertet werden; 16 in der Pivampicillin/Pivmecillinam- und 18 in der Placebogruppe. Sieben Patienten der Pivampicillin/Pivmecillinam-Gruppe mußten nach 10–25 Tagen die Behandlung beenden, da Nebenwirkungen, vor allem in Form von Exanthemen und Übelkeit, auftraten. Während einer Nachbeobachtungszeit von 13 bis 20 Wochen waren bei 8/16 der mit Pivampicillin/Pivmecillinam und 4/18 der mit Placebo behandelten Patienten im Stuhl keine Salmonellen mehr nachweisbar. Bei den Patienten, die auf die Behandlung nicht ansprachen, fand sich außer zwei Fällen von vorausgegangener Cholezystektomie in der Pivampicillin/Pivmecillinam-Gruppe keine Auffälligkeiten.
Similar content being viewed by others
References
Buchwald, D. S., Blaser, M. J. A review of human salmonellosis: II. Duration of excretion following infection with nontyphi salmonella. Rev. Infect. Dis. 6 (1984) 345–356.
Ekwall, E., Jonsson, M. A comparison of the combination pivmecillinam/pivampicillin and co-trimoxazole in the treatment of convalescent carriers of salmonella and shigella. Scand. J. Infect. Dis. 16 (1984) 99–102.
Petterson, T., Klemola, E., Wager, O. Treatment of acute cases of salmonella infection and salmonella carriers with ampicillin and neomycin. Acta. Med. Scand. 175 (1964) 185–190.
Franzen, C., Lidin-Janson, G., Nygren, B. Trimethoprim — sulphamethoxazole in enteric infections. Scand. J. Infect. Dis. 4 (1972) 231–240.
Diridl, G., Pichler, H., Wolf, D. Treatment of chronic salmonella carriers with ciprofloxacin. Eur. J. Clin. Microbiol. 5 (1986) 260–261.
Ferreccio, C., Morris, J. G., Valdivieso, C., Prenzel, I., Sotomayor, V., Drusano, G. L., Levine, M. M. Efficacy of ciprofloxacin in the treatment of chronic typhoid carriers. J. Infect. Dis. 157 (1988) 1235–1239.
Gotuzzo, E., Guerra, J. G., Benavente, L., Palomino, J. C., Carrillo, C., Lopera, J., Delgado, F., Nalin, D. R., Sabbaj, J. Use of norfloxacin to treat chronic typhoid carriers. J. Infect. Dis. 157 (1988) 1221–1225.
Lähdevirta, J.: Ciprofloxacin in the elimination of enteric salmonella carriage stage. Scand. J. Infect. Dis. (Suppl. 60) (1989) 112–115.
Rodriguez-Noriega, E., Andrade-Villanueva, J., Amaya-Tapia, G. Quinolones in the treatment of salmonella carriers. Rev. Infect. Dis. 11 (Suppl. 5) (1989) 1179–1187.
Sammalkorpi, K., Lähdevirta, J., Mäkelä, T., Rostila, T. Treatment of chronic salmonella carriers with ciprofloxacin. Lancet ii (1987) 164–165.
Ewing, W. H. Edward's and Ewing's identification of Enterobacteriaceae, 4th edition. Elsevier Science Publishing Co., Inc, New York 1986, pp. 186–202.
Ericsson, H. M., Sherris, J. C. Antibiotic sensitivity testing. Acta. Pathol. Microbiol. Scand. (B) (Suppl. 217) (1971) 1–90.
Limson, B. M., Mendoza, M. T., Liwanag, E., Christensen, O. E., Menday, P. Randomised, comparative trial of mecillinam, mecillinam/ampicillin and chloramphenicol in the treatment of enteric fever. J. Antimicrob. Chemother. 9 (1982) 405–410.
Tanphaichitra, D., Srimuang, S., Chiaprasittigul, P., Menday, P., Christensen, O. The combination of pivmecillinam and pivampicillin in the treatment of enteric fever. Infection 12 (1984) 381–383.
Limson, B. M., Littaua, R. T. Comparative study of ciprofloxacin versus co-trimoxazole in the treatment of salmonella enteric fever. Infection 17 (1989) 105–106.
Schluter, G. Ciprofloxacin: Review of potential toxicologic effects. Am. J. Med. 82 (Suppl. 4 A) (1987) 91–93.
Svenungsson, B., Goffe, G. Persistent excretion of salmonella in foreign-born adopted and native Swedish children. Scand. J. Infect. Dis. 22 (1990) 37–42.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Svenungsson, B., Ekwall, E. & Hansson, H.B. Efficacy of the combination pivampicillin/pivmecillinam compared to place-bo in the treatment of convalescent carriers of nontyphi salmonella. Infection 18, 163–165 (1990). https://doi.org/10.1007/BF01642105
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01642105